Last reviewed · How we verify
Tegoprazan 50 mg, tablets, orally, bid
Tegoprazan 50 mg, tablets, orally, bid is a Small molecule drug developed by Zhang Xiaofeng,MD. It is currently FDA-approved.
Tegoprazan 50 mg is an orally administered tablet, dosed twice daily, currently marketed by Dr. Zhang Xiaofeng. The drug's key composition patent is set to expire in 2028, providing a period of market exclusivity. The primary risk is the potential for increased competition once the patent expires.
At a glance
| Generic name | Tegoprazan 50 mg, tablets, orally, bid |
|---|---|
| Sponsor | Zhang Xiaofeng,MD |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Tegoprazan-Based Therapies for H. Pylori Eradication: A Randomized Controlled Trial (NA)
- Tegoprazan-Amoxicillin Dual Therapy vs. Bismuth Quadruple Therapy for H. Pylori Infection (TATH-1) (PHASE4)
- PK and PD Interaction Between Tegoprazan and NOACs After Multiple Oral Dosing in Healthy Volunteers (PHASE1)
- Drug Interaction Study Between Tegoprazan, Bismuth, Amoxicillin and Clarithromycin (PHASE1)
- Pharmacokinetic Interaction Between Tegoprazan and NSAIDs After Multiple Oral Dosing in Healthy Male Volunteers (PHASE1)
- Evaluate the PK of Multiple Oral Doses of Tegoprazan, Metronidazole, Tetracycline and Bismuth in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tegoprazan 50 mg, tablets, orally, bid CI brief — competitive landscape report
- Tegoprazan 50 mg, tablets, orally, bid updates RSS · CI watch RSS
- Zhang Xiaofeng,MD portfolio CI